LY-53857 is a serotonin 5-HT2 receptor antagonist of the ergoline family which has been widely used in scientific research. It is a potent antagonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors (Ki = 7.2–50 nM, 6.3–6.9 nM, and 7.9–8.3 nM, respectively). The drug shows strong selectivity for the serotonin 5-HT2 receptors over the serotonin 5-HT1 and α-adrenergic receptors. Although originally thought to be selective for the serotonin 5-HT2 receptors, LY-53857 was subsequently found to also show significant affinity for the serotonin 5-HT7 receptor (Ki = 100 nM), where it is likewise an antagonist. In addition, it shows high affinity for the serotonin 5-HT1F receptor (Ki = 6.87 nM). It produces antidepressant-like and anxiolytic-like effects in rodents. The drug has no effect on locomotor activity by itself, but blocks the hyperlocomotion induced by phencyclidine (PCP). In addition, whereas meta-chlorophenylpiperazine (mCPP) produces hypolocomotion by itself, the combination of mCPP with LY-53857 results in mCPP producing hyperlocomotion instead. LY-53857 blocks the discriminative stimulus of the psychedelic drugs LSD, mescaline, and DOM in rodent drug discrimination studies. The drug inhibits the hyperthermia induced by the psychedelic drug DOI, by mCPP, and by the serotonin releasing agent para-chloroamphetamine (PCA). Analogues of LY-53857 have also been described and include LY-86057 (the N1-desisopropyl analogue), LY-108742 (the N1-methyl analogue), and LY-197541 (the N1-isobutyl analogue). LY-53857 was first described in the scientific literature by 1979.
See also Substituted ergoline LY-86057 Amesergide (LY-237733) LY-215840 Sergolexole (LY-281067) LA-3Cl-SB
References
External links LY-53,857 - Isomer Design


